重组牛碱性成纤维细胞生长因子眼用凝胶联合妥布霉素地塞米松滴眼液治疗白内障术后干眼症患者的临床研究  

Clinical trial of recombinant bovine basic fibroblast growth factor eye gel combined with tobramycin-dexamethasone eye drops in the treatment of patients with dry eye syndrome after cataract surgery

作　　者：安琪 应晔 洪浩 AN Qi;YING Ye;HONG Hao(Department of Ophthalmology,Nanjing Second Hospital,Nanjing 210003,Jiangsu Province,China)

机构地区：[1]南京市第二医院眼科,江苏南京210003

出　　处：《中国临床药理学杂志》2023年第16期2316-2319,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察重组牛碱性成纤维细胞生长因子眼用凝胶联合妥布霉素地塞米松滴眼液治疗白内障超声乳化(CUP)术后干眼症(DES)的效果。方法将CUP术后DES患者分为试验组和对照组。试验组给予重组牛碱性成纤维细胞生长因子眼用凝胶联合妥布霉素地塞米松滴眼液治疗;对照组给予重组牛碱性成纤维细胞生长因子眼用凝胶治疗,均持续治疗1个月。比较2组治疗前后眼表疾病指数量表(OSFI)评分、角膜荧光染色(CFS)评分、泪膜破裂时间(BUT)、基础泪液分泌试验(SIT)、泪膜厚度(TFT)和血清白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平及药物不良反应发生情况。结果试验组37例,对照组51例。试验组和对照组治疗后的OSFI评分分别为(19.45±2.12)和(29.30±2.08)分,CFS评分分别为(3.59±0.46)和(5.60±0.67)分,IL-1β分别为(35.23±5.49)和(60.31±6.27)ng·L^(-1),IL-6分别为(0.97±0.14)和(1.43±0.28)ng·L^(-1),TNF-α分别为(115.71±18.64)和(193.50±21.07)ng·L^(-1),BUT分别为(8.45±0.36)和(7.38±0.75)s,SIT分别为(10.17±1.23)和(8.94±0.86)mm/5 min,TFT分别为(29.78±2.04)和(26.53±2.36)μm,差异均有统计学意义(均P<0.05)。试验组与对照组的药物不良反应发生率分别为18.18%和11.36%(P>0.05)。结论重组牛碱性成纤维细胞生长因子眼用凝胶与妥布霉素地塞米松滴眼液联合用于CUP术后DES,可改善泪膜稳定性,且不增加药物不良反应发生率。Objective To explore the clinical effect of recombinant bovine basic fibroblast growth factor eye gel combined with tobramycin-dexamethasone eye drops on dry eye syndrome(DES)after cataract ultrasonic phacoemulsification(CUP).Methods Patients with DES after CUP were divided into treatment group and control group.Treatment group was given recombinant bovine basic fibroblast growth factor eye gel combined with tobramycin-dexamethasone eye drops;control group was given recombinant bovine basic fibroblast growth factor eye gel.All were treated for 1 month.The scores of ocular surface disease index(OSFI)and corneal fluorescence staining(CFS),break up time(BUT),schirmer I test(SIT),tear film thickness(TFT),levels of serum interleukin-1β(IL-1β),interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α),and adverse reactions were compared between the two groups before and after treatment.Results There were 37 cases in treatment group and 51 cases in control group.After treatment,OSFI scores in treatment group and control group were(19.45±2.12)and(29.30±2.08)seore,CFS scores were(3.59±0.46)and(5.60±0.67)seore,IL-1βlevels were(35.23±5.49)and(60.31±6.27)ng·L^(-1),IL-6 levels were(0.97±0.14)and(1.43±0.28)ng·L^(-1),TNF-αlevels were(115.71±18.64)and(193.50±21.07)ng·L^(-1),TFT were(8.45±0.36)and(7.38±0.75)s,SIT were(10.17±1.23)and(8.94±0.86)mm/5 min,BUT were(29.78±2.04)and(26.53±2.36)μm,the differences were all statistically significant(all P<0.05).There was no significant difference in incidence of adverse drug reactions between treatment group and control group(18.18%vs 11.36%,P>0.05).Conclusion Recombinant bovine basic fibroblast growth factor eye gel combined with tobramycin-dexamethasone eye drops can improve stability of tear film in patients with DES after CUP,with low incidence of adverse drug reactions.

关 键 词：重组牛碱性成纤维细胞生长因子眼用凝胶 妥布霉素地塞米松滴眼液 白内障超声乳化 干眼症 泪膜稳定性 

分 类 号：R97[医药卫生—药品]